Salvage treatment of HCV patients by Sofosbuvir, Daclatasvir, Simeprevir and Ribavirin after repeated treatment failures is associated with SVR and reduced risk of hepatocellular carcinoma

被引：0
|
作者：
Hanafy, A. [1 ]
Abd-Elsalam, S. [2 ]
Soliman, S. [3 ]
机构：
[1] Zagazig Univ, Fac Med, Internal Med Hepatol & Endoscopy Div, Zagazig, Egypt
[2] Tanta Univ, Trop Med, Tanta, Egypt
[3] Menoufia Univ, Publ Hlth, Al Minufya, Egypt
来源：
JOURNAL OF HEPATOLOGY | 2018年 / 68卷
关键词：
D O I：
10.1016/S0168-8278(18)30805-5
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
THU-365
引用
收藏
页码：S293 / S294
页数：2
相关论文
共 50 条
  • [41] RESIDUAL HCV-RNA IN LIVER EXPLANTS FROM PATIENTS UNDERGOING SOFOSBUVIR AND RIBAVIRIN TREATMENT WHILE AWAITING LIVER TRANSPLANTATION IS NOT ASSOCIATED WITH HCV RELAPSE
    Gambato, M.
    Perez-del-Pulgar, S.
    Hedskog, C.
    Svarovskia, J.
    Paulson, M. S.
    Denning, J.
    Curry, M. P.
    Caro-Perez, N.
    Londono, M. C.
    Forns, X.
    DIGESTIVE AND LIVER DISEASE, 2015, 47 : E11 - E11
  • [42] Incidence of Hepatocellular Carcinoma after Treatment with Sofosbuvir-Based or Sofosbuvir-Free Regimens in Patients with Chronic Hepatitis C
    Ogawa, Eiichi
    Nomura, Hideyuki
    Nakamuta, Makoto
    Furusyo, Norihiro
    Kajiwara, Eiji
    Dohmen, Kazufumi
    Kawano, Akira
    Ooho, Aritsune
    Azuma, Koichi
    Takahashi, Kazuhiro
    Satoh, Takeaki
    Koyanagi, Toshimasa
    Ichiki, Yasunori
    Kuniyoshi, Masami
    Yanagita, Kimihiko
    Amagase, Hiromasa
    Morita, Chie
    Sugimoto, Rie
    Kato, Masaki
    Shimoda, Shinji
    Hayashi, Jun
    CANCERS, 2020, 12 (09) : 1 - 13
  • [43] Letter: safety and efficacy of sofosbuvir plus daclatasvir with ribavirin for 12weeks in Chinese treatment-experienced cirrhotic genotype 1b patients with HCV
    Zeng, Q. -L.
    Li, C. -X.
    Zhang, D. -W.
    Li, W.
    Xu, G. -H.
    Yu, Z. -J.
    ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2016, 43 (07) : 842 - 843
  • [44] Post-treatment liver stiffness measurement is not useful to predict hepatocellular carcinoma in HCV patients who achieve SVR
    Shili, S.
    Giovanna, S.
    Foucher, J.
    Anne, V.
    Jean-Baptiste, H.
    Francois, M.
    Chermak, F.
    Bernard, P. -H.
    De Ledinghen, V.
    Hezode, C.
    JOURNAL OF HEPATOLOGY, 2018, 68 : S14 - S14
  • [45] COST-EFFECTIVENESS ANALYSIS OF DACLATASVIR/SOFOSBUVIR (DCV/SOF) FOR THE TREATMENT OF HCV PATIENTS WHO FAILED AFTER FIRST LINE TREATMENT WITH SECOND GENERATION OF DAA IN ITALY
    Ruggeri, M.
    Rolli, F. R.
    Coretti, S.
    Kondili, L.
    De Solda, F.
    Nappi, C.
    Cicchetti, A.
    VALUE IN HEALTH, 2017, 20 (09) : A787 - A788
  • [46] The outcome of combined treatment with ombitasvir-paritaprevir-ritonavir, sofosbuvir with or without ribavirin as salvage therapy for Egyptian HCV experienced patients: A single center study
    Ismail, Waleed Abdelfattah
    Wadea, Fady Maher
    DRUG DISCOVERIES AND THERAPEUTICS, 2018, 12 (06): : 368 - 373
  • [47] High post-treatment absolute monocyte count predicted hepatocellular carcinoma risk in HCV patients who failed peginterferon/ribavirin therapy
    Chen, Tsung-Ming
    Lin, Chun-Che
    Huang, Pi-Teh
    Wen, Chen-Fan
    TUMOR BIOLOGY, 2016, 37 (06) : 7129 - 7137
  • [48] Risk of de novo Hepatocellular Carcinoma after HCV Treatment with Direct-Acting Antivirals
    Finkelmeier, Fabian
    Dultz, Georg
    Peiffer, Kai-Henrik
    Kronenberger, Bernd
    Krauss, Franziska
    Zeuzem, Stefan
    Sarrazin, Christoph
    Vermehren, Johannes
    Waidmann, Oliver
    LIVER CANCER, 2018, 7 (02) : 190 - 204
  • [49] Treatment Response to 12 Weeks of Simeprevir plus Sofosbuvir±Ribavirin (SMV plus SOF±RBV): A Meta-Analysis of 7 Studies With 715 HCV Genotype 1 (HCV-1) Patients
    Yee, Brittany E.
    Nghia Nguyen
    Lutchman, Glen
    Lim, Joseph K.
    Nguyen, Mindie H.
    GASTROENTEROLOGY, 2015, 148 (04) : S1088 - S1089
  • [50] SVR is the strongest predictor of occurrence and recurrence of hepatocellular carcinoma in HCV cirrhotic patients after treatment with DAAs: a prospective multi-centric Italian study
    Lleo, A.
    Aglitti, A.
    Ciancio, A.
    Di Marco, V.
    Aghemo, A.
    Lampertico, P.
    Brunetto, M.
    Zuin, M. G.
    Andreone, P.
    Villa, E.
    Troshina, G.
    Calvaruso, V.
    Degasperi, E.
    Coco, B.
    Giorgini, A.
    Conti, F.
    Di Leo, A.
    Marzi, L.
    Boccaccio, V.
    Bollani, S.
    Maisonneuve, P.
    Rendina, M. G.
    Persico, M.
    Bruno, S.
    JOURNAL OF HEPATOLOGY, 2018, 68 : S86 - S86
12345